Researchers found that inhibiting GSK-3 led to less defects in the axonal transport process and less neuronal cell death, while inhibiting ERK1 led to more transport problems and more cell death.

CHINO HILLS, CALIFORNIA / ACCESS Newswire / May 6, 2025 / SOHM, Inc. (OTC PINK:SHMN), a biotech company at the forefront of precision cellular engineering, announced today the successful development o ...

CHINO HILLS, CALIFORNIA / ACCESS Newswire / May 6, 2025 /SOHM, Inc. (OTC PINK:SHMN), a biotech company at the forefront of precision cellular engineering, announced today the successful development of ...

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In ...

University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated huntingtin protein (HTT) cause Huntington's disease?

University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated huntingtin ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated ...